Both Waters and Applied Biosystems were bombarded with questions from analysts regarding their mass spectrometers when they reported their quarterly earnings last month. However, the reasons for this intense scrutiny differed: While ABI reported an “extraordinary increase in mass spectrometry revenue of more than 50 percent over the prior year period,” Waters stated that its mass spec business for the quarter was down by a percentage “in the double digits,” compared to last year’s quarter.